PD-1

[OSE Immunotherapeutics SA] OSE Immunotherapeutics SA announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi®, a combination of neoepitopes, for use after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients.

[Clinical and Translational Oncology] Pretreated specimens were evaluated by immunohistochemistry for programmed cell death protein 1 and its ligand, densities of tumor infiltrative lymphocytes, as well as c-MYC and Ki-67 expressions.

[Expert Opinion On Biological Therapy] The authors present completed and ongoing research projects regarding prostate cancer immunotherapy. Ipilimumab and olaparib were proved to prolong overall survival significantly against placebo, but a lot of research is going on to identify which patients and at what stage of disease will benefit the most before incorporating them in clinical practice.

[Current Oncology Reports] The authors review the current role for CTLA-4 inhibitors in early-stage resectable NSCLC, unresectable stage III NSCLC, and in metastatic NSCLC.

[Clinical Cancer Research] Researchers used mass cytometry by time-of-flight, flow cytometry, and T cell receptor immunosequencing to conduct simultaneous single-cell analyses of immune cells in the sentinel lymph nodes of melanoma patients.

[Advanced Materials] IFN-γ treatment induced remarkable PD-L1 expression on PD-L1-expressing macrophage membrane (PRM), thereby allowing PRM nanodecoys to bind mPD-1 on CD4+ T cell surfaces or neutralize free sPD-1, which reconstructed the PD-1/PD-L1 inhibitory axis to suppress CD4+ T cell activation and restore immune tolerance.